Research from industry analyst GlobalData finds that the market for regenerative medicines will expand in the coming years to reach $16.4 billion in annual revenues.
The expansion over the forecast period to 2026 is driven largely by cell and gene therapies, with 53 such products currently available and a further 175 pipeline agents under development.
The gene therapy segment was valued at $734 million across the largest mature markets in 2019, and is forecast to reach $13.3 billion by 2026.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze